MLV & Co. Upgrades Cytokinetics (CYTK) to Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Cytokinetics (CYTK) Posts Narrower than Expected Q3 Loss
October 31, 2014 9:08 AM EDTCytokinetics (NASDAQ: CYTK) reported Q3 EPS of ($0.16), $0.07 better than the analyst estimate of ($0.23). Revenue for the quarter came in at $9.4 million versus the consensus estimate of $7.43 million.
"In the third quarter, Cytokinetics made considerable progress across our development stage programs as we elaborated in our... More
